Skip To Main Content
Harendra Kumar Shah on Muck Rack

Harendra Kumar Shah

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Harendra Kumar

Contact Harendra Kumar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The TROP2 targeting antibody-drug conjugate IMMU-132 enhances the efficacy of radiation therapy for lung cancer

|
By Ron Bose, Abhay Kumar Singh, Vaishali Kapoor, Harendra Kumar Shah, Sai Prem
| Nature Verified
Abstract Studies suggest that the human trophoblast cell-surface antigen (TROP2) is highly expressed in most lung cancers and is associated with poor prognosis. Currently, there are no TROP2-directed ADCs approved for the treatment of lung cancer patients. IMMU-132 ADC (Sacituzumab govitecan) is a TROP-2-directed ADC recently approved for metastatic triple-negative breast cancer and urothelial cancer. However, its role in non-small cell carcinoma (NSCLC) has not been explored.
Open in Who Shared Issue with article?
See all 1 articles